

Stereo Selectivity of Histaminic Receptors Play an Important Role of Anti-histaminic Activity

Rezk R. Ayyad¹, Ahmed M. Mansour², Ahmed M. Nejm¹, Yasser Abdel Allem Hassan³ & Ahmed R. Ayyad⁴

¹ Pharmaceutical Medicinal Chemistry Department, Faculty of Pharmacy, ALAZHAR University, Cairo, Egypt

² Pharmacology and Toxicology Department, Faculty of Pharmacy, ALAZHAR University, Cairo, Egypt

³ Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Addaqahlya, Egypt

⁴ Faculty of Medicine, Asfendiyarov, Almaty, Kazakh, National Medical University (KazNMU) Correspondence: Rezk R. Ayyad, Pharmaceutical Medicinal Chemistry Department, Faculty of Pharmacy, ALAZHAR University, Cairo, Egypt.

doi:10.56397/CRMS.2024.03.02

Abstract

The histamine is a natural compound derived from histidine and amino acid which act on different histaminic receptors (H1, H2, H3 and H4), each receptor combined with histamine and give the different actions especially H1 and H2 receptors.

The action of each depends on the specificity of the receptors, e.g., the compounds which act on H1 receptor are similar to each other but different than the compounds which act on H2 receptor (due to the difference between two receptors from the area and stereo of the receptors).

Keywords: Histaminic receptors, H1, H2, H3 and H4, chiral carbon, lipid solubility, anti- histaminic activity, H1 antagonists and H2 antagonists

1. Introduction

The histamine is a natural body substance resulted from decarboxylation of the amino acid called histidine. The histamine reveal some physiological functions in some tissues in the body where cause vasodilatation and may be release some transient matters which cause hypersensitivity, may increase the acidity due to increase the hydrochloric acid from the stomach. The histamine acts on four receptors which present in the body (stomach H2, mainly skin and others H1, CNS H3 and H4 receptor subtype responsible for the immunity). The more famous of histaminic receptors are H1 and H2 where the physiological activity of the histamine appears obviously at these receptors H1 and H2 where the hypersensitivity (itching, flushing and inflammation of skin, anaphylaxis, catarrhal symptoms) and hyper acidity and peptic ulcer respectively. The examine of H1 and H2 receptors present the difference of compounds which act on these receptors, the


compounds act on H1 receptors are diphenhydramine, clemastine, pheniramine, chlorpheniramine, triprolidine, dimethindene, tripelennamine, antazoline, buclizine, hydroxyzine, promethazine, pimethixene, cyproheptadine, ketotifen, terfenadine, fexofenadine, acrivastine and cetirizine, while the compounds act on H2 receptor are cimetidine, ranitidine, nizatidine, famotidine, and burimamide.

From the previous drugs we note the chemical structure differences of the H1 antagonists and H2 antagonists explain the stereo selectivity of histaminic receptors, hence the activity of anti-histaminics different according to the receptor.

2. Chemistry and Pharmacology


H1 antagonists include the anti-histaminics which used in treatment of hypersensitivity and allergy, also anaphylactic shock. Because the stereo selectivity of the receptor, the H1 antagonist must be contain at least four atoms e.g. Ethylenediamine or ethanolamine these examples four atoms compounds at least.

Diphenhydramine.




This drug has amine attached to two carbons and oxygen, this compound used in management of hypersensitivity and many types of urticaria.

Clemastine fumarate.




Clemastine fumarate is H1 antagonist explain the stereo selectivity of H1 receptor where it contains chiral carbon and used as other anti-histamine.

Pheniramine maleate.




This compound also showed the stereo selectivity of H1 receptor, and also used as anti-allergic (different types) and antihypersensitivity.


Chlorpheniramine maleate.



The same pharmacological action of pheniramine maleate but has long duration and high lipid solubility.


Triprolidine.





In addition to anti histaminic its anti-emetic and anti-vertigo activities and has chiral carbon which make it optical active compound, also explain the stereo selectivity of histamine receptors.

Hydroxyzine.




Its optical active compound has H1 antagonist and metabolized into cetirizine which also optical active compound, they are indicated to stero selectivity of the receptors.

Promethazine HCL (phenothiazine derivative).

Dimethindene.

This compound is H1 antagonist and has geometrical isomerism.




Dimethindene is H1 antagonist and its medicinal uses as previous compounds, also explain the stereo selectivity of histaminic receptor (its levo enantiomer).

Buclizine.




In addition to its H1 antagonist activity, it has tranquilizer which potentiate the analgesic activity of analgesics and anti-emetic activity, this drug has optical activity and prove of the stereo selectivity of H1 receptor.

Pimethixene.




It is analogue of promethazine but has geometrical isomerism.

Cyproheptadine HCL.




In addition to H1 antagonist it has anti-serotonergic activity (tricyclic anti-depressant and appetite stimulant and has geometrical isomerism). Ketotifen.



One of these H1 antagonist in addition to mast cell stabilizer so used in prophylaxis against bronchial asthma, not merely but has geometrical isomerism.


Terfenadine.



One of H1 antagonist which has optical activity, but also has one side effect is cardiac arrhythmia, so it is withdrawn from the market.


N.B. Its metabolite *FEXOFENADINE* not produce cardiac arrhythmia and has H1 antagonist, optical active compound.

Acrivastine.



One of these drugs which has H1 antagonist and has geometrical isomerism.


Loratadine.



activity, inhibit CYP-450 enzymes so delayed the metabolism of drugs which metabolized by CYP-450 and interfere with anti-acids.


N.B. This drug has imidazole ring which similar to histamine.

Ranitidine.




H2 antagonist has furan ring.

Famotidine.




Nizatidine.



N.B. Famotidine and nizatidine H2 antagonist and has thiazole ring.

Burimamide.



N.B. The Burimamide is the prototype of H2 antagonist but it has the major side effect (agranulocytosis), so it is not clinically used.

3. Conclusion

H1 ANTAGONISTS AND H2 antagonists are similar in some chemical features and many of them have stereo chemistry. All of these antagonists either H1 or H2 explain stereo selectivity.

References


A Ibrahim, HM Sakr, RR Ayyad, MM Khalifa.

Loratadine non-sedative anti-histaminic and has geometrical isomerism.

N.B. All H1 antagonist has lipid solubility which is indicate to penetrate the cell and reach to the action wanted, these compounds mainly fitted with H1 receptor due to the chemical structure which required for H1 receptor, as well as the optical or geometrical isomerism of them.

All the above characteristics indicate to stereo selectivity of the H1 receptor comparing with H2 antagonists as following.

Cimetidine.



One of the H2 antagonists in spite it has chemical structure near to H1 antagonists, this indicates also to stereo selectivity of H2 antagonists, the cimetidine has anti-androgenic (2022). Design, Synthesis, In-Vivo Anti-Diabetic Activity, In-Vitro α -Glucosidase Inhibitory Activity and Molecular Docking Studies of Some Quinazolinone Derivatives. *ChemistrySelect*, 7(14), e202104590.

Abdel-Aziz, A. A. M., El-Azab, A. S., Alanazi, A. M., Asiri, Y. A., Al-Suwaidan, I. A., Maarouf, A. R., ... & Shawer, T. Z. (2016). Synthesis and potential antitumor activity of 7-(4-substituted

piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies. *Journal of Enzyme Inhibition and Medicinal Chemistry*, *31*(5), 796-809.

Abdel-Aziz, A. A. M., El-Azab, A. S., Alanazi, A. M., Asiri, Y. A., Al-Suwaidan, I. A., Maarouf, A. R., ... & Shawer, T. Z. (2016). Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 31(5), 796-809.

- AGA El-Helby, H Sakr, RRA Ayyad, K El-Adl, MM Ali, F Khedr. (2018). Anti-Cancer Agents Med. *Chem*, *18*(8), 1184.
- Al Ward, M., Abdallah, A. E., Zayed, M., Ayyad, R., & El-Zahabi, M. (2023). New immunomodulatory anticancer quinazolinone based thalidomide analogs: Design, synthesis and biological evaluation.
- Alaa, A. M., El-Azab, A. S., Abou-Zeid, L. A., ElTahir, K. E. H., Abdel-Aziz, N. I., Ayyad, R. R., & Al-Obaid, A. M. (2016). Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5, 5-diphenylimidazolidine-2, 4-dione scaffold: molecular docking studies. *European journal* of medicinal chemistry, 115, 121-131.
- Alanazi, A. M., Abdel-Aziz, A. A. M., Shawer, T. Z., Ayyad, R. R., Al-Obaid, A. M., Al-Agamy, M. H., ... & El-Azab, A. S. (2016). Synthesis, antitumor and antimicrobial activity of some new 6-methyl-3-phenyl-4 (3 H)-quinazolinone analogues: in silico studies. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 31(5), 721-735.
- Al-Suwaidan, I. A., Abdel-Aziz, A. A. M., Shawer, T. Z., Ayyad, R. R., Alanazi, A. M., El-Morsy, A. M., ... & El-Azab, A. S. (2016). Synthesis, antitumor activity and molecular

docking study of some novel 3-benzyl-4 (3H) quinazolinone analogues. *Journal of enzyme inhibition and medicinal chemistry*, 31(1), 78-89.

- Al-Warhi, T., Almahli, H., Maklad, R. M., Elsayed, Z. M., El Hassab, M. A., Alotaibi, O. J., ... & El-Ashrey, M. K. (2023).
 1-Benzyl-5-bromo-3-hydrazonoindolin-2-on es as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights. *Molecules*, 28(7), 3203.
- Al-Warhi, T., El Kerdawy, A. M., Aljaeed, N., Ismael, O. E., Ayyad, R. R., Eldehna, W. M., ... & Al-Ansary, G. H. (2020). Synthesis, biological evaluation and in silico studies of certain oxindole–indole conjugates as anticancer CDK inhibitors. *Molecules*, 25(9), 2031.
- Ayyad, R. (2012). Synthesis and Biological Evaluation of Novel Iodophthalazinedione Derivatives as Anticonvulsant Agents. *Al-Azhar Journal of Pharmaceutical Sciences*, 45(1), 1-13.
- Ayyad, R. (2014). Synthesis and Anticonvulsant Activity of 6-Iodo Phthalazinedione Derivatives. *Al-Azhar Journal of Pharmaceutical Sciences*, 50(2), 43-54.
- Ayyad, R. A., Sakr, H. M., & El-Gamal, K. M. (2016). Design, Synthesis, Computer Modeling and Analgesic Activity of Some New Disubstituted Quinazolin-4 (3H)-ones. *Med. Chem*, 6(5), 299-305.
- Ayyad, R. A., Sakr, H., & El-Gamal, K. (2016). Synthesis, modeling and anticonvulsant activity of some phthalazinone derivatives. *American Journal of Organic Chemistry*, 6(1), 29-38.
- Ayyad, R. R., Nejm, A. M., Abdelaleem, Y. H., & Ayyad, A. R. (2023). Hydrophobicity, Transport and Target Sites of Action Are Important for the Activity of Many Drugs. *Current Research in Medical Sciences*, 2(3), 15-19.
- Ayyad, R. R., Sakr, H. M., El-Gamal, K. M., Eissa, I. H., HA, A., Tita, A. S., ... & Mansour, A. M. (2017). Anti-Inflammatory, Proton Pump Inhibitor and Synthesis of Some New Benzimidazole Derivatives. *Der Chemica Sinica*, 8(1), 184-97.
- Ayyad, R., Sakr, H., & Gaafer, A. (2022). Design and Synthesis of New Compounds Derived from Phenyl Hydrazine and Different

Aldehydes as Anticancer Agents. *International Journal of Organic Chemistry*, 12(1), 28-39.

- Eissa, I. H., Metwaly, A. M., Belal, A., Mehany, A. B., Ayyad, R. R., El-Adl, K., ... & ElSohly, M. A. (2019). Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors. *Archiv der Pharmazie*, 352(11), 1900123.
- El-Adl, K., El-Helby, A. G. A., Ayyad, R. R., Mahdy, H. A., Khalifa, M. M., Elnagar, H. A., ... & Eissa, I. H. (2021). Design, synthesis, and anti-proliferative evaluation of new quinazolin-4 (3H)-ones as potential VEGFR-2 inhibitors. *Bioorganic & Medicinal Chemistry*, 29, 115872.
- El-Adl, K., El-Helby, A. G. A., Sakr, H., Ayyad, R. R., Mahdy, H. A., Nasser, M., ... & El-Hddad, S. S. (2021). Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2, 4-dichloro) benzylidene] thiazolidine-2, 4-dione derivatives as VEGFR-2 inhibitors. *Archiv der Pharmazie*, 354(2), 2000279.
- El-Azab, A. S., Alaa, A. M., Ayyad, R. R., Ceruso, M., & Supuran, C. T. (2016). Inhibition of carbonic anhydrase isoforms I, II, IV, VII and XII with carboxylates and sulfonamides incorporating phthalimide/phthalic anhydride scaffolds. *Bioorganic & medicinal chemistry*, 24(1), 20-25.
- Eldehna, W. M., Abo-Ashour, M. F., Al-Warhi, T., Al-Rashood, S. T., Alharbi, A., Ayyad, R. R., ... & El-Haggar, R. (2021). Development of

2-oxindolin-3-ylidene-indole-3-carbohydraz ide derivatives as novel apoptotic and anti-proliferative agents towards colorectal cancer cells. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 36(1), 320-329.

- Eldehna, W. M., Salem, R., Elsayed, Z. M., Al-Warhi, T., Knany, H. R., Ayyad, R. R., ... & El-Haggar, R. (2021). Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 36(1), 1423-1434.
- Elhelby, A. A., Ayyad, R. R., & Zayed, M. F. (2011). Synthesis and biological evaluation

of some novel quinoxaline derivatives as anticonvulsant agents. *Arzneimittelforschung*, *61*(07), 379-381.

- El-Helby, A. A., Ibrahim, M. K., Abdel-Rahman, A. A., Ayyad, R. R. A., Menshawy, M. A., & El-Adl, K. (2009). Synthesis, molecular modeling and anticonvulsant activity of benzoxazole derivatives. *Al-Azhar J Pharm Sci*, 40, 252-70.
- El-Helby, A. G. A., Ayyad, R. R., El-Adl, K., & Elkady, H. (2019). Phthalazine-1, 4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking. *Molecular diversity*, 23, 283-298.
- El-Helby, A. G. A., Ayyad, R. R., El-Adl, K., & Elwan, A. (2017). Quinoxalin-2 (1 H)-one derived AMPA-receptor antagonists: Design, synthesis, molecular docking and anticonvulsant activity. *Medicinal Chemistry Research*, *26*, 2967-2984.
- El-Helby, A. G. A., Ayyad, R. R., El-Adl, K., Sakr, H., Abd-Elrahman, A. A., Eissa, I. H., & Elwan, A. (2016). Design, molecular docking and synthesis of some novel 4-acetyl-1-substituted-3, 4-dihydroquinoxalin-2 (1 H)-one derivatives anticonvulsant evaluation for as AMPA-receptor antagonists. Medicinal Chemistry Research, 25, 3030-3046.
- El-Helby, A. G. A., Ayyad, R. R., Sakr, H. M., Abdelrahim, A. S., El-Adl, K., Sherbiny, F. S., ... & Khalifa, M. M. (2017). Design, synthesis, molecular modeling and biological evaluation of novel 2, 3-dihydrophthalazine-1, 4-dione derivatives as potential anticonvulsant agents. *Journal of Molecular Structure*, 1130, 333-351.
- El-Helby, A. G. A., Ayyad, R. R., Sakr, H., El-Adl, K., Ali, M. M., & Khedr, F. (2017). design, synthesis, molecular docking, and anticancer activity of phthalazine derivatives as VEGFR-2 inhibitors. *Archiv der Pharmazie*, 350(12), 1700240.
- El-Helby, A. G. A., Ayyad, R. R., Zayed, M. F., Abulkhair, H. S., Elkady, H., & El-Adl, K. (2019). Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants. *Archiv Der Pharmazie*, 352(5), 1800387.

El-Helby, A. G. A., Sakr, H., Ayyad, R. R., El-Adl,

K., Ali, M. M., & Khedr, F. (2018). Design, synthesis, in vitro anti-cancer activity, ADMET profile and molecular docking of novel triazolo 4-a] phthalazine [3, derivatives targeting VEGFR-2 enzyme. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer 18(8), Agents), 1184-1196.

- El-Helby, A. G. A., Sakr, H., Ayyad, R. R., Mahdy, H. A., Khalifa, M. M., Belal, A., ... & Eissa, I.
 H. (2020). Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. *Bioorganic chemistry*, 103, 104233.
- H Mahdy, M Shaat, R Ayyad. (2022). RECENT ADVANCES IN DRUGS TARGETING PROTEIN KINASES FOR CANCER THERAPY. *Al-Azhar Journal of Pharmaceutical Sciences*, 66(2), 56-86.

Ibrahim, M. K., Abd-Elrahman, A. A., Ayyad, R. R., El-Adl, K., Mansour, A. M., & Eissa, I. H. (2013). Design and synthesis of some novel 2-(3-methyl-2-oxoquinoxalin-1 (2H)-yl)-N-(4-(substituted) phenyl) acetamide derivatives for biological evaluation as anticonvulsant agents. *Bulletin of Faculty of Pharmacy, Cairo University*, 51(1), 101-111.

- Ibrahim, M. K., El-Helby, A. E. A., Ghiaty, A. H., Biomy, A. H., Abd-El Rahman, A. A., Ayyad, R. R., & Menshawy, M. A. MODELING, SYNTHESIS AND ANTIHYPERGLYCEMIC ACTIVITY OF NOVEL QUINAZOLINONES CONTAINING SULFONYLUREA.
- Khalifa, M. M., Sakr, H. M., Ibrahim, A., Mansour, A. M., & Ayyad, R. R. (2022). synthesis Design and of new benzylidene-quinazolinone hybrids as potential anti-diabetic agents: In vitro α -glucosidase inhibition, and docking studies. Journal of Molecular Structure, 1250, 131768.
- M Sakr, H., R Ayyad, R., Mahmoud, K., M Mansour, A., & Ahmed, G. (2021). Design, Synthesis of Analgesics and Anticancer of Some New Derivatives of Benzimidazole. *International Journal of Organic Chemistry*, 11(03), 144-169.

- Nassar, E., El-Badry, Y. A., Eltoukhy, A. M. M., & Ayyad, R. R. (2016). Synthesis and Antiproliferative Activity of 1-(4-(1H-Indol-3-Yl)-6-(4-Methoxyphenyl) Pyrimidin-2-yl) Hydrazine and Its Pyrazolo Pyrimidine Derivatives. *Med chem* (*Los Angeles*), *6*, 224-233.
- Osman, I. A., Ayyad, R. R., & Mahdy, H. A. (2022). New pyrimidine-5-carbonitrile derivatives as EGFR inhibitors with anticancer and apoptotic activities: design, molecular modeling and synthesis. *New Journal of Chemistry*, 46(24), 11812-11827.
- RR Ayyad, AM Nejm, AR Ayyad. (2023). The Activity of Some Antibiotics Depend on Stereochemistry of Them (Its Structure). *Journal of Progress in Engineering and Physical Science*, 2(2), 5-7.
- RR Ayyad, AM Nejm, AR Ayyad. (2023). The Isomers of Some Drugs One Effective and the Other Is Toxic or Ineffective. *Current Research in Medical Sciences*, 2(2), 58-62.
- Sakr, H., Ayyad, R. R., El-Helby, A. A., Khalifa, M. M., & Mahdy, H. A. (2021). Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors. *Archiv der Pharmazie*, 354(6), 2000456.
- Salem, M. M., Ayyad, R., & Sakr, H. (2022). Design and Synthesis of Some New Oxadiazole Derivatives as Anticancer Agents. *International Journal of Organic Chemistry*, 12(02), 64-74.
- Zayed, M. F., & Ayyad, R. R. (2012). Some novel anticonvulsant agents derived from phthalazinedione. *Arzneimittelforschung*, 62(11), 532-536.